摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S)-2-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-b]pyridin-2-yl)butan-1-ol | 477940-25-3

中文名称
——
中文别名
——
英文名称
(2S)-2-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-b]pyridin-2-yl)butan-1-ol
英文别名
2(S)-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-b]pyridin-2-yl)butanol;2(S)-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-b]pyridin-2-yl)butan-1-ol;(S)-[1-(hydroxy-oxazolo[4,5-b]pyridin-2-yl-methyl)-propyl]-carbamic acid tert-butyl ester;tert-butyl N-[(2S)-1-hydroxy-1-([1,3]oxazolo[4,5-b]pyridin-2-yl)butan-2-yl]carbamate
(2S)-2-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-b]pyridin-2-yl)butan-1-ol化学式
CAS
477940-25-3
化学式
C15H21N3O4
mdl
——
分子量
307.349
InChiKey
RSMRLGVUDZWPMH-FTNKSUMCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    454.3±45.0 °C(Predicted)
  • 密度:
    1.218±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    97.5
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES PEPTIDIQUES EN TANT QU'INHIBITEURS DE LA PROTEASE A CYSTEINE
    申请人:AXYS PHARM INC
    公开号:WO2004000838A1
    公开(公告)日:2003-12-31
    The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱氨酸蛋白酶的化合物,特别是卡特普辛B、K、L、F和S,因此在治疗由这些蛋白酶介导的疾病方面具有用途。本发明涉及包含这些化合物的药物组合物以及制备它们的方法。
  • Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof
    申请人:AXYS PHARMACEUTICALS, INC.
    公开号:US20040019218A1
    公开(公告)日:2004-01-29
    The present invention is directed to a novel process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents that are useful in the synthesis of a variety of pharmaceuticals, in particular certain cysteine protease inhibitors.
    本发明涉及一种新型制备杂环烯基和不饱和杂环烷基镁试剂的方法,该方法在合成多种药物,特别是某些半胱氨酸蛋白酶抑制剂方面具有用途。
  • Novel compounds and compositions as cathepsin inhibitors
    申请人:——
    公开号:US20030105099A1
    公开(公告)日:2003-06-05
    The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
    本发明涉及新型卡特普西林S抑制剂、其药学上可接受的盐和N-氧化物,它们作为治疗剂的用途以及它们的制备方法。
  • Cysteine protease inhibitors
    申请人:Graupe Michael
    公开号:US20050288336A1
    公开(公告)日:2005-12-29
    The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱氨酸蛋白酶的化合物,特别是cathepsin B、K、L、F和S,因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的过程。
  • Peptidic compounds as cysteine protease inhibitors
    申请人:AXYS PHARMACEUTICALS, INC.
    公开号:US20040127426A1
    公开(公告)日:2004-07-01
    The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱氨酸蛋白酶的化合物,特别是抑制B、K、L、F和S型猫蛋白酶,因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和其制备方法。
查看更多

同类化合物

甲基吡噁磷 甲基吡啶磷-d6 恶唑并[5,4-B]吡啶-2-胺二盐酸盐 恶唑并[5,4-B]吡啶-2-胺 恶唑并[5,4-B]吡啶-2(1H)-硫酮 恶唑并[4,5-B]吡啶-2(3H)硫酮 噁唑并[5,4-c]吡啶-2-胺 噁唑并[5,4-c]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶 噁唑并[4,5-c]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-羧酸乙酯 噁唑并[4,5-b]吡啶-2(3H)-酮,6-溴-3-(苯基甲基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,6-乙酰基-3-[2-(2-吡啶基)乙基]- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-羰基丙基)- 噁唑并[4,5-b]吡啶,2-(1-甲基乙基)-(9CI) 噁唑并[4,5-b]吡啶 噁唑并[4,5-C]吡啶-2(3H)-硫酮 噁唑并[4,5-C]吡啶 [1,3]恶唑并[4,5-c]吡啶-6-羧酸 7-溴恶唑并[4,5-C]吡啶 7-溴-2-甲基-F唑并[4,5-C]吡啶 7-溴-2-乙基恶唑并[4,5-C]吡啶 6-溴恶唑并[5,4-B]吡啶-2-胺 6-溴恶唑并[5,4-B]吡啶 6-溴噁唑并[4,5-b]吡啶 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 6-溴-2-甲基噁唑并[5,4-b]吡啶 6-溴-2-甲基噁唑并[4,5-B]吡啶 6-溴-2-(三氟甲基)噁唑并[5,4-B]吡啶 6-溴-2-(三氟甲基)噁唑并[4,5-b]吡啶 6-氯恶唑并[4,5-b]吡啶-2(3H)-酮 5-甲基噁唑并[4,5-b]吡啶-2(3h)-酮 5-甲基-3H-恶唑并[4,5-B]吡啶-2-硫酮 5-溴-3H-恶唑并[4,5-b]吡啶-2-酮 3-[2-(4-氯苯基)乙基]-2-苯基亚氨基-1,3-噻唑烷-4-酮 3-(2-溴乙基)恶唑并[4,5-b]吡啶-2(3H)-酮 3-(2-吗啉-4-基乙基)[1,3]噁唑并[4,5-b]吡啶-2(3H)-酮 2-甲硫基唑并[4,5-B]吡啶 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 2-甲基噁唑并[5,4-c]吡啶 2-甲基噁唑并[5,4-b]吡啶 2-甲基吡啶并噁唑 2-甲基[1,3]噁唑并[4,5-b]吡啶 2-氯甲基噁唑并[4,5-b]吡啶 2-氯恶唑并[5,4-b]吡啶 2-氯恶唑并[5,4-C]吡啶盐酸盐 2-氯恶唑并[5,4-C]吡啶 2-氯噁唑并[4,5-B]吡啶